Manufacturing Contracts

MDS Nordion offers tailored solutions, leading expertise, and service capabilities for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development.

Our past and present commercial partnerships have been integral to our success to date and are key to our future growth.

Imaging

 Partner Partner's Product Medical Isotope Services and Expertise  
Avid Radiopharmaceuticals 123I β-amyloid compound
Avid is developing novel radiopharmaceuticals to diagnose and monitor Alzheimer's disease and other pathologies.		 Iodine-123
  • Radiolabelling feasibility
Alseres Pharmaceuticals Altropane®
The Altropane molecular imaging agent is being developed to aid in the diagnosis of Parkinson's Disease.		 Iodine-123
  • Process development
  • Scale-up
  • Clinical supply
Molecular Insight Pharmaceuticals Zemiva™ (Iodofiltic Acid I123)
Zemiva is being developed to detect and manage cardiac ischemia by imaging metabolic changes in the heart.		 Iodine-123
  • Process development
  • Scale-up
  • Clinical supply
CardioGen-82 is the only generator-based, cardiac Positron Emission Tomography (PET) perfusion imaging agent approved by the FDA. Using a specialized generator technology, it produces Rubidium-82, used to examine blood flow through heart vessels. Rubidium-82
  • Process development
  • Scale-up
  • Commercial supply
Imaging services based on Annexin, an imaging agent that binds to cells undergoing apoptosis. Iodine-125 Iodine-123
  • Molecular imaging

Therapy

 Partner Partner's Product Medical Isotope Services and Expertise  
Bradmer Pharmaceuticals Neuradiab (I-131 anti-
tenascin 81C6 mAb)
Bradmer Pharmaceuticals' novel molecular targeting agent under development for the treatment of Glioblastoma Multiforme (GBM).		 Iodine-131
  • Process development
  • Scale-up
  • Clinical trial manufacture
GlaxoSmithKline Bexxar® (Iodine I131Tositumomab)
The Bexxar Therapeutic Regimen is indicated for the treatment of patients with CD 20 antigen expressing relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma (NHL), including patients with Rituximab-refractory non-Hodgkin's lymphoma.		 Iodine-131
  • Process development
  • Scale-up
  • Manufacture
Cell Therapeutics, Inc. Zevalin® (Ibritumomab Tiuxetan)
Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, including patients with Rituximab-refractory follicular NHL.		 Yttrium-90
  • Development of Yttrium-90 Chloride Sterile Solution for clinical and commercial distribution
Hologic Iotrex® Radiotherapy Solution (I125 HBS)
Iotrex is a radiotherapy solution to be used in the GliaSite® Radiation Treatment Delivery System, indicated for the treatment of newly diagnosed, metastatic and recurrent brain tumors be delivering radiation from within the cavity created by the surgical removal of the tumor.		 Iodine-125
  • Process development
  • Manufacture
Molecular Insight Pharmaceuticals Azedra™ (Ultratrace™ Iobenguane I131)
Under development for the treatment of neuroblastoma and pheochromacytoma.		 Iodine-131
  • Process development